SCHEMBL5577291

SCHEMBL5577291

COC(=O)C(Cc1cc(C)cc(C)c1)[C@H](NC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 6/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.40
MDM4 O15151 1/20 0.39
MDM2 Q00987 1/20 0.39
F10 P00742 2/20 0.37
SLC7A5 Q01650 1/20 0.36
CTSB P07858 2/20 0.36
CTSL P07711 1/20 0.36
CTSS P25774 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CACNA1F O60840 1/20 0.35
CACNA1D Q01668 1/20 0.35
CACNA1S Q13698 1/20 0.35
CACNA1C Q13936 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5577212 0.89 MEN1 (0.50) KMT2AMEN1MDM4MDM2ATM
SCHEMBL5577227 0.79 MEN1 (0.46) KMT2AMEN1ALDH1A1
SCHEMBL5577564 0.79 SMN1; SMN2 (0.40) KMT2AMEN1F10L3MBTL1ALDH1A1
SCHEMBL5577888 0.76 HTR2A (0.38) KMT2AMEN1F10
SCHEMBL18307298 0.74 KMT2A (0.44) KMT2AMEN1ALDH1A1PTGS1PTGS2
SCHEMBL5413934 0.73 KMT2A (0.43) KMT2ACTSLCTSSL3MBTL1PTGS1
SCHEMBL5413928 0.73 KMT2A (0.43) KMT2ACTSLCTSSL3MBTL1PTGS1
SCHEMBL1109144 0.73 KMT2A (0.43) KMT2ACTSLCTSSL3MBTL1PTGS1
SCHEMBL12379297 0.73 KMT2A (0.43) KMT2ACTSLCTSSL3MBTL1PTGS1
SCHEMBL1105488 0.73 KMT2A (0.43) KMT2ACTSLCTSSL3MBTL1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142467-A1 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission THE UNIVERSITY OF MONTANA (US) 2007-06-21 US disclosed
WO-2006047251-A2 3-ALKYLARYL ASPARTATE COMPOUNDS AND THEIR USE FOR SELECTIVE ENHANCEMENT OF SYNAPTIC TRANSMISSION THE UNIVERSITY OF MONTANA (US) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142467-A1 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission SLC1A1, SLC1A3, SLC1A2 TACR1 1348/4885KMT2A 1036/4885MEN1 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.